These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 36618922)

  • 1. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
    Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
    Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer].
    Saito A; Yonemori K
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):695-701. PubMed ID: 39191683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Therapeutic Advances in Gynecologic Oncology: A Review.
    Wilson EM; Eskander RN; Binder PS
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Nerone M; Grande MD; Sessa C; Colombo I
    Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Coleman N; Yap TA; Heymach JV; Meric-Bernstam F; Le X
    NPJ Precis Oncol; 2023 Jan; 7(1):5. PubMed ID: 36631624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer - The ABCs of ADCs (Antibody drug Conjugates).
    Martin J; Zacholski E; O'Cearbhaill R; Matulonis U; Chen L
    Gynecol Oncol Rep; 2023 Feb; 45():101141. PubMed ID: 36818197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art.
    Camarda F; Paderno M; Cannizzaro MC; Nero C; Sabatucci I; Fucà G; Musacchio L; Salutari V; Scambia G; Lorusso D
    Ther Adv Med Oncol; 2024; 16():17588359241277647. PubMed ID: 39323928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer.
    Yu Y; Wang J; Liao D; Zhang D; Li X; Jia Y; Kong F
    Breast Cancer (Dove Med Press); 2022; 14():417-432. PubMed ID: 36532256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer.
    Nucera S; Conti C; Martorana F; Wilson B; Genta S
    Biomedicines; 2024 Jul; 12(7):. PubMed ID: 39062065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tisotumab vedotin for the treatment of cervical carcinoma.
    Song X; Li R; Wang H; Song P; Guo W; Chen ZS
    Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
    Luu K; Chu A; Chang B
    J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tisotumab vedotin in recurrent or metastatic cervical cancer.
    Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
    Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
    Gogia P; Ashraf H; Bhasin S; Xu Y
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.